[Combination effect of KW-2228 and aminoglycoside antibiotics on systemic infection in cyclophosphamide-treated tumor-bearing mice].
A modified recombinant human granulocyte colony-stimulating factor (rhG-CSF), KW-2228, has some excellent properties such as high specific activity in stimulating granulocyte colony-formation in vitro, great biological stability in plasma, good pharmacokinetic profile and high potency in granulopoiesis in normal mice in vivo. Recently, the application of G-CSF against infectious diseases has been considered, and some animal experiments have been carried out to support its clinical applications. Patients with underlying diseases such as leukemia and cancer often have recurrent infections because of reduced numbers or functions of neutrophils, which mediate an early stage of host defense. In out present study, we established a new method to evaluate in vivo potency of G-CSF in colon 26 tumor-bearing mice. By using the method, we examined combination effects of KW-2228 with aminoglycoside antibiotics against a systemic infection caused by Pseudomonas aeruginosa. KW-2228 (1 microgram/mouse/day) was administered (s.c.) once a day for 4 days before the bacterial infection was introduced in colon 26 tumor-bearing mice receiving cyclophosphamide 3 days after the transplantation of tumor. Antibiotics were administered (s.c.) 2 hours after the introduction of the bacterial infection. ED50 of gentamicin (GM) alone and that of the combination with KW-2228 were 40.7 mg/kg and 3.6 mg/kg, respectively. ED50 of astromicin (ASTM) alone and that of the combination with KW-2228 were 386 mg/kg and 17.8 mg/kg, respectively. Thus the combination therapy of KW-2228 with GM or ASTM exhibited excellent protective effects in comparison to the treatment with antibiotic alone.(ABSTRACT TRUNCATED AT 250 WORDS)
Yoshino
T
T
Pharmaceutical Research Laboratories, Kyowa Hakko Kogyo Co., Ltd.
Sato
K
K
D000617:Aminoglycosides; D000818:Animals; D000900:Anti-Bacterial Agents / Q000008:administration & dosage*; D003520:Cyclophosphamide / Q000009:adverse effects*; D004359:Drug Therapy, Combination; D005839:Gentamicins / Q000008:administration & dosage*; D016179:Granulocyte Colony-Stimulating Factor / Q000008:administration & dosage*; D008297:Male; D051379:Mice; D008807:Mice, Inbred BALB C; D009368:Neoplasm Transplantation; D009374:Neoplasms, Experimental / Q000150:complications* / Q000188:drug therapy; D009503:Neutropenia / Q000150:complications; D011552:Pseudomonas Infections / Q000188:drug therapy*; D011994:Recombinant Proteins / Q000008:administration & dosage
D000617:Aminoglycosides; D000900:Anti-Bacterial Agents; D005839:Gentamicins; D011994:Recombinant Proteins; D016179:Granulocyte Colony-Stimulating Factor; C023384:fortimicin A; D003520:Cyclophosphamide; C072115:nartograstim